168 related articles for article (PubMed ID: 25767277)
1. FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Yakkundi A; Bennett R; Hernández-Negrete I; Delalande JM; Hanna M; Lyubomska O; Arthur K; Short A; McKeen H; Nelson L; McCrudden CM; McNally R; McClements L; McCarthy HO; Burns AJ; Bicknell R; Kissenpfennig A; Robson T
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):845-54. PubMed ID: 25767277
[TBL] [Abstract][Full Text] [Related]
2. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Valentine A; O'Rourke M; Yakkundi A; Worthington J; Hookham M; Bicknell R; McCarthy HO; McClelland K; McCallum L; Dyer H; McKeen H; Waugh DJ; Roberts J; McGregor J; Cotton G; James I; Harrison T; Hirst DG; Robson T
Clin Cancer Res; 2011 Mar; 17(5):1044-56. PubMed ID: 21364036
[TBL] [Abstract][Full Text] [Related]
3. The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
Yakkundi A; McCallum L; O'Kane A; Dyer H; Worthington J; McKeen HD; McClements L; Elliott C; McCarthy HO; Hirst DG; Robson T
PLoS One; 2013; 8(2):e55075. PubMed ID: 23457460
[TBL] [Abstract][Full Text] [Related]
4. Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.
Hooper AT; Shmelkov SV; Gupta S; Milde T; Bambino K; Gillen K; Goetz M; Chavala S; Baljevic M; Murphy AJ; Valenzuela DM; Gale NW; Thurston G; Yancopoulos GD; Vahdat L; Evans T; Rafii S
Circ Res; 2009 Jul; 105(2):201-8. PubMed ID: 19542015
[TBL] [Abstract][Full Text] [Related]
5. Targeted Disruption of JCAD (Junctional Protein Associated With Coronary Artery Disease)/KIAA1462, a Coronary Artery Disease-Associated Gene Product, Inhibits Angiogenic Processes In Vitro and In Vivo.
Hara T; Monguchi T; Iwamoto N; Akashi M; Mori K; Oshita T; Okano M; Toh R; Irino Y; Shinohara M; Yamashita Y; Shioi G; Furuse M; Ishida T; Hirata KI
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1667-1673. PubMed ID: 28705794
[TBL] [Abstract][Full Text] [Related]
6. Endothelial deletion of phospholipase D2 reduces hypoxic response and pathological angiogenesis.
Ghim J; Moon JS; Lee CS; Lee J; Song P; Lee A; Jang JH; Kim D; Yoon JH; Koh YJ; Chelakkot C; Kang BJ; Kim JM; Kim KL; Yang YR; Kim Y; Kim SH; Hwang D; Suh PG; Koh GY; Kong YY; Ryu SH
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1697-703. PubMed ID: 24947526
[TBL] [Abstract][Full Text] [Related]
7. Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis.
Lee SH; Lee S; Yang H; Song S; Kim K; Saunders TL; Yoon JK; Koh GY; Kim I
Circ Res; 2014 Jul; 115(2):215-26. PubMed ID: 24755984
[TBL] [Abstract][Full Text] [Related]
8. Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
Todd N; McNally R; Alqudah A; Jerotic D; Suvakov S; Obradovic D; Hoch D; Hombrebueno JR; Campos GL; Watson CJ; Gojnic-Dugalic M; Simic TP; Krasnodembskaya A; Desoye G; Eastwood KA; Hunter AJ; Holmes VA; McCance DR; Young IS; Grieve DJ; Kenny LC; Garovic VD; Robson T; McClements L
J Clin Endocrinol Metab; 2021 Jan; 106(1):26-41. PubMed ID: 32617576
[TBL] [Abstract][Full Text] [Related]
9. Etv2 and fli1b function together as key regulators of vasculogenesis and angiogenesis.
Craig MP; Grajevskaja V; Liao HK; Balciuniene J; Ekker SC; Park JS; Essner JJ; Balciunas D; Sumanas S
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):865-76. PubMed ID: 25722433
[TBL] [Abstract][Full Text] [Related]
10. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
11. PKN3 is the major regulator of angiogenesis and tumor metastasis in mice.
Mukai H; Muramatsu A; Mashud R; Kubouchi K; Tsujimoto S; Hongu T; Kanaho Y; Tsubaki M; Nishida S; Shioi G; Danno S; Mehruba M; Satoh R; Sugiura R
Sci Rep; 2016 Jan; 6():18979. PubMed ID: 26742562
[TBL] [Abstract][Full Text] [Related]
12. Loss of Expression of Antiangiogenic Protein FKBPL in Endometrioid Endometrial Carcinoma: Implications for Clinical Practice.
Obradović DD; Milić NM; Miladinović N; McClements L; Oprić DM
Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295491
[TBL] [Abstract][Full Text] [Related]
13. FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function.
Alqudah A; Eastwood KA; Jerotic D; Todd N; Hoch D; McNally R; Obradovic D; Dugalic S; Hunter AJ; Holmes VA; McCance DR; Young IS; Watson CJ; Robson T; Desoye G; Grieve DJ; McClements L
Front Endocrinol (Lausanne); 2021; 12():650328. PubMed ID: 34149611
[TBL] [Abstract][Full Text] [Related]
14. LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming.
Ren B; Best B; Ramakrishnan DP; Walcott BP; Storz P; Silverstein RL
Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1197-208. PubMed ID: 27013613
[TBL] [Abstract][Full Text] [Related]
15. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
16. FKBPL: a marker of good prognosis in breast cancer.
Nelson L; McKeen HD; Marshall A; Mulrane L; Starczynski J; Storr SJ; Lanigan F; Byrne C; Arthur K; Hegarty S; Ali AA; Furlong F; McCarthy HO; Ellis IO; Green AR; Rakha E; Young L; Kunkler I; Thomas J; Jack W; Cameron D; Jirström K; Yakkundi A; McClements L; Martin SG; Gallagher WM; Dunn J; Bartlett J; O'Connor D; Robson T
Oncotarget; 2015 May; 6(14):12209-23. PubMed ID: 25906750
[TBL] [Abstract][Full Text] [Related]
17. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis.
Clere N; Corre I; Faure S; Guihot AL; Vessières E; Chalopin M; Morel A; Coqueret O; Hein L; Delneste Y; Paris F; Henrion D
Int J Cancer; 2010 Nov; 127(10):2279-91. PubMed ID: 20143398
[TBL] [Abstract][Full Text] [Related]
18. Loss of stromal JUNB does not affect tumor growth and angiogenesis.
Braun J; Strittmatter K; Nübel T; Komljenovic D; Sator-Schmitt M; Bäuerle T; Angel P; Schorpp-Kistner M
Int J Cancer; 2014 Mar; 134(6):1511-6. PubMed ID: 24027048
[TBL] [Abstract][Full Text] [Related]
19. Calpastatin counteracts pathological angiogenesis by inhibiting suppressor of cytokine signaling 3 degradation in vascular endothelial cells.
Miyazaki T; Taketomi Y; Saito Y; Hosono T; Lei XF; Kim-Kaneyama JR; Arata S; Takahashi H; Murakami M; Miyazaki A
Circ Res; 2015 Mar; 116(7):1170-81. PubMed ID: 25648699
[TBL] [Abstract][Full Text] [Related]
20. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
